Literature DB >> 17089312

Predictive risk factors in double-valve replacement (AVR and MVR) compared to isolated aortic valve replacement.

J Litmathe1, U Boeken, M Kurt, P Feindt, E Gams.   

Abstract

BACKGROUND: The operative risk of combined aortic and mitral surgery is still between 5 and 13 %, whereas isolated AVR normally causes complications in less than 4 % of all patients. Thus, it was the aim of the study to compare both procedures and to evaluate risk stratification in our patient cohort. PATIENTS AND METHODS: The inhospital mortality and complication rates were analyzed in both groups over a period of 4 years. There were 396 patients with isolated AVR, and 98 patients with AVR and MVR. For both groups, we investigated 16 possible risk factors for perioperative death or severe complications, such as low cardiac output syndrome (LCOS). The risk factors were analyzed by univariate analysis, and factors with P < 0.01 were entered into a multivariate analysis.
RESULTS: There were 11/396 perioperative deaths in patients with AVR (2.8 %) compared to 5/98 (5.1 %) in DVR. The incidence of major complications was 5.3 % in AVR vs. 11.2 % in DVR. As risk factors ( P < 0.05) for death, we found in AVR: former cardiac surgery, aortic stenosis, and pulmonary arterial pressure > 55 mmHg. In patients with DVR, we additionally found: left atrial pressure (LAP) > 20 mmHg and creatinine > 2 mg/dl. Risk factors for severe complications in AVR were: former cardiac surgery and creatinine > 2 mg/dl, in cases of DVR, additionally: tricuspid valve disease (TVD) and LAP > 20 mmHg.
CONCLUSIONS: Our analysis of risk factors shows that in patients with DVR preoperative parameters, which sometimes are estimated to be unimportant, may cause an adverse outcome. The operation should be carried out before reaching advanced or even end-stage heart failure, and more attention should be paid to an individual perioperative concept and optimized myocardial protection in such patients.

Entities:  

Mesh:

Year:  2006        PMID: 17089312     DOI: 10.1055/s-2006-924247

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  6 in total

1.  Wall Thickness, Pulmonary Hypertension, and Diastolic Filling Abnormalities Predict Response to Postoperative Biventricular Pacing.

Authors:  Robin M Brusen; Rebecca Hahn; Santos E Cabreriza; Bin Cheng; Daniel Y Wang; Wanda Truong; Henry M Spotnitz
Journal:  J Cardiothorac Vasc Anesth       Date:  2015-02-07       Impact factor: 2.628

2.  Clinical and echocardiographic features of paradoxical low-flow and normal-flow severe aortic stenosis patients with concomitant mitral regurgitation.

Authors:  Jinghao Nicholas Ngiam; Nicholas Chew; Rebecca Teng; Jonathan D Kochav; Stephanie M Kochav; Benjamin Yong-Qiang Tan; Hui Wen Sim; Ching-Hui Sia; William K F Kong; Edgar Lik Wui Tay; Tiong-Cheng Yeo; Kian-Keong Poh
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-27       Impact factor: 2.357

3.  Quantitative evaluation of change in coexistent mitral regurgitation after aortic valve replacement.

Authors:  David J Kaczorowski; John W Macarthur; Jessica Howard; Dale Kobrin; Alex Fairman; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-11       Impact factor: 5.209

4.  Should high risk patients with concomitant severe aortic stenosis and mitral valve disease undergo double valve surgery in the TAVR era?

Authors:  Pey-Jen Yu; Allan Mattia; Hugh A Cassiere; Rick Esposito; Frank Manetta; Nina Kohn; Alan R Hartman
Journal:  J Cardiothorac Surg       Date:  2017-12-29       Impact factor: 1.637

5.  Outcomes of transcatheter aortic valve replacement in patients with mitral valve regurgitation.

Authors:  Obai Abdullah; Jad Omran; Ashraf Al-Dadah; Tariq Enezate
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-06-26       Impact factor: 1.426

6.  Combined Mitral and Aortic Valve Surgery: 17-year Experience in a Single Center.

Authors:  Annastiina Husso; Teemu Riekkinen; Aino Rissanen; Juho Ollila; Antti Valtola
Journal:  Scand J Surg       Date:  2021-01-18       Impact factor: 2.360

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.